Viva Biotech and Lonza Enter Licensing Agreement for Lonza's bYlok® Bispecific Pairing Technology

News

}

Home / News / Company News / Company News detail

Time: 2024-03-20

Source: Viva Biotech

[Abstract]:Accessing this technology expands Viva Biotech's large molecule capabilities by supporting the design and production of bispecific antibodies.

Recently, Viva Biotech (Shanghai) Co., Ltd. ("Viva Biotech") entered into a license agreement with Lonza to obtain access to Lonza's bYlok® bispecific pairing technology. This demonstrates Viva Biotech's drive to improve the production of bispecific antibodies and bring these therapies to clinic.

Lonza's bYlok® technology is an innovative bispecific antibody design solution to overcome the industry-wide challenge of heavy-light chain mispairing. Lonza's bYlok® technology enhances the production efficiency and quality of bispecific antibodies, thereby facilitating the development of these next-generation molecules. Accessing this technology expands Viva Biotech's large molecule capabilities by supporting the design and production of bispecific antibodies.

（Technical Process）

Dr. Xinyu Deng, Vice President of Viva Biotech: “We are delighted to enter into this bYlok® bispecific antibody technology licensing agreement with Lonza. The production of bispecific antibodies can face significant challenges in terms of mispairing and downstream processing. Lonza's bYlok® technology platform effectively addresses these challenges by supporting the design, development and large-scale production of bispecific antibodies, without compromising on cost and time to market. Using Lonza's bYlok® technology is expected to enhance the efficiency and success of our bispecific-related drug development programs.”

Previous Page：Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future Next Page：AIxplorerBio published a research article in the J. Comput. Chem. on enhancing the efficiency of relative binding free energy calculation, with Dr. Yue Qian as the co-corresponding author.

Back

Media contact: vivapr@vivabiotech.com

This site uses cookies and your privacy choices are important to us

We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.